Frontiers in nephrologyPub Date : 2026-09-24eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1943229
T Wagner, Hauke Heinrich, E Schober, L Ischebeck, N Schleussner, M Hummels, F C Koehler, C Kurschat, M Kann, C Bruns, D L Stippel, M N Thomas
{"title":"Post-transplant ureteral stenosis: donor-related risk factors, graft outcome and surgical management.","authors":"T Wagner, Hauke Heinrich, E Schober, L Ischebeck, N Schleussner, M Hummels, F C Koehler, C Kurschat, M Kann, C Bruns, D L Stippel, M N Thomas","doi":"10.3389/fneph.2026.1943229","DOIUrl":"10.3389/fneph.2026.1943229","url":null,"abstract":"<p><strong>Introduction: </strong>Kidney transplantation remains the preferred treatment for end-stage renal disease; however, the increasing use of extended-criteria donors has been associated with a higher incidence of postoperative complications.</p><p><strong>Methods: </strong>We retrospectively analyzed 471 kidney transplant recipients at the University of Cologne between 2012 and 2022 to evaluate the incidence, risk factors, clinical outcomes, and surgical management of ureteral stenosis.</p><p><strong>Results: </strong>Ureteral stenosis occurred in 6.37% and was significantly associated with older donor age within the extended-criteria donor range (65 vs. 56 years, p = 0.006), multiple renal arteries (33.3% vs. 10.2%, p < 0.001), and BK virus infection, as reflected by higher rates of BK viruria (26.7% vs. 7.0%, p = 0.002) and BK viraemia (26.7% vs. 8.6%, p = 0.005). Renal function was significantly impaired in recipients with ureteral stenosis at 6 months, 1 year, and 2 years after transplantation. Death-censored graft survival was significantly lower in the stenosis group (79.7% vs. 93.3%, p = 0.01).</p><p><strong>Discussion: </strong>Ureteral transposition and ureteroneocystostomy demonstrated comparable outcomes, long-term renal function and graft survival supporting individualization of surgical technique based on anatomical and patient-specific factors.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1943229"},"PeriodicalIF":2.9,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-24eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1918450
Altynay Balmukhanova, Chee Eng Chan, Jonathan Barratt
{"title":"Complement biomarkers in IgA nephropathy: current insights and clinical relevance.","authors":"Altynay Balmukhanova, Chee Eng Chan, Jonathan Barratt","doi":"10.3389/fneph.2026.1918450","DOIUrl":"10.3389/fneph.2026.1918450","url":null,"abstract":"<p><p>IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and is a major contributor to the global burden of chronic kidney disease. Strong evidence highlights complement activation as a key driver of the disease pathogenesis and its progression. In this regard, the emergence of new therapies targeting the complement system has further increased interest in specific biomarkers that can help in diagnosis, prognosis, and assessment of response to therapy in patients with IgAN. Although complement biomarkers show promising associations with disease severity and prognosis, most remain exploratory and lack adequate validation for routine clinical application. Further research should focus on standardization and prospective multicenter validation of putative biomarkers to facilitate a biomarker-driven approach to the use of complement inhibitors in IgAN. Therefore, this review summarizes a growing body of evidence on the role of complement-related biomarkers in IgAN and discusses their diagnostic and prognostic potential, as well as several limitations for implementation in clinical practice.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1918450"},"PeriodicalIF":2.9,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13647163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-21eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1931478
Luli Zheng, Guokai Yang
{"title":"The lactate dehydrogenase-to-albumin ratio is independently associated with moderate-to-severe tubulointerstitial fibrosis in patients with IgA nephropathy.","authors":"Luli Zheng, Guokai Yang","doi":"10.3389/fneph.2026.1931478","DOIUrl":"https://doi.org/10.3389/fneph.2026.1931478","url":null,"abstract":"<p><strong>Background: </strong>Tubulointerstitial fibrosis accelerates the progression of immunoglobulin A nephropathy (IgAN) to end-stage renal disease (ESRD). While renal biopsy is the standard for evaluation, non-invasive biomarkers remain scarce. This study investigated the independent association and diagnostic value of the lactate dehydrogenase-to-albumin ratio (LAR) for moderate-to-severe tubulointerstitial fibrosis (Oxford T1+T2) in IgAN patients.</p><p><strong>Methods: </strong>We retrospectively analyzed 398 patients with biopsy-proven primary IgAN, categorized into no/mild fibrosis (T0, n=273) and moderate-to-severe fibrosis (T1+T2, n=125) groups. Clinical, laboratory, and pathological data were collected to calculate LAR. Missing data were handled using multiple imputation by chained equations (MICE). Statistical evaluations included logistic regression, ROC curves, restricted cubic splines (RCS), and subgroup analyses.</p><p><strong>Results: </strong>The T1+T2 group exhibited significantly higher median LAR levels (5.10 vs. 4.13, P < 0.001). Following adjustment for confounders, LAR remained independently associated with fibrosis (OR = 1.425, 95% CI: 1.122-1.809, P = 0.004). The AUC was 0.717, with an optimal cut-off of 4.91 (sensitivity 56.8%, specificity 78.0%). RCS analysis indicated a linear relationship (P for non-linearity = 0.2350). Subgroup analyses showed consistent positive associations (OR > 1.2), reaching statistical significance in males, patients aged ≥40 years, and those with eGFR ≥60 mL/min/1.73 m². Sensitivity analyses confirmed robustness. Patients with LAR > 4.91 demonstrated worse renal function, heavier proteinuria, and higher fibrosis incidence (54.2% vs. 20.2%, P < 0.001).</p><p><strong>Conclusion: </strong>LAR is independently associated with moderate-to-severe tubulointerstitial fibrosis and demonstrates moderate diagnostic efficacy. As a cost-effective indicator, LAR may serve as a non-invasive auxiliary tool for clinical screening and risk stratification in IgAN, but it cannot replace renal biopsy as the diagnostic gold standard.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1931478"},"PeriodicalIF":2.9,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-18eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1977844
Domenico Cerullo, Sonia Fiori, Manuel Alfredo Podestà
{"title":"Editorial: Advancement in kidney care: targeted delivery and precision medicine approaches.","authors":"Domenico Cerullo, Sonia Fiori, Manuel Alfredo Podestà","doi":"10.3389/fneph.2026.1977844","DOIUrl":"https://doi.org/10.3389/fneph.2026.1977844","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1977844"},"PeriodicalIF":2.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-18eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1932419
Fernando Sánchez-Morán, Salvador Pérez, Juan Sastre-Belloch, María Lidón Mateu-Campos
{"title":"Beyond renal support: biological modulation across pathophysiological domains during continuous renal replacement therapy - a randomized pilot study.","authors":"Fernando Sánchez-Morán, Salvador Pérez, Juan Sastre-Belloch, María Lidón Mateu-Campos","doi":"10.3389/fneph.2026.1932419","DOIUrl":"10.3389/fneph.2026.1932419","url":null,"abstract":"<p><strong>Background: </strong>Continuous renal replacement therapy (CRRT) is the preferred extracorporeal renal support modality for haemodynamically unstable critically ill patients with acute kidney injury (AKI). Although regional citrate anticoagulation (RCA) is primarily used to maintain circuit patency, its biological effects may extend beyond anticoagulation itself. We hypothesized that different anticoagulation strategies are associated with distinct biological modulation across complementary pathophysiological domains during CRRT.</p><p><strong>Methods: </strong>We conducted a prospective randomized pilot trial comparing RCA with systemic unfractionated heparin in critically ill adults with AKI requiring CRRT (1:1 allocation). Serial blood samples were obtained before CRRT initiation, at 1 hour and at 24 hours, with paired pre- and post-filter sampling at 1 and 24 hours. Biomarkers represented redox homeostasis (glutathione -GSH, GSSG- and their ratio), neutrophil activation (myeloperoxidase -MPO-), cellular injury (cell-free DNA -cfDNA-) and systemic inflammation (C-reactive protein -CRP-). Healthy reference participants established physiological reference values. Longitudinal analyses used linear mixed-effects models with fixed effects for time, anticoagulation strategy and their interaction. This trial was registered in the European Clinical Trials Database (EudraCT No. 2016-004361-12) and at ClinicalTrials.gov (NCT06646328).</p><p><strong>Results: </strong>Twenty patients were randomized equally to RCA or systemic heparin; baseline characteristics were comparable between groups. Among six biomarkers spanning four pathophysiological domains, only MPO showed a significant systemic time × anticoagulation interaction (P = .008); although baseline-adjusted sensitivity analyses did not confirm a significant between-group difference. GSH and cfDNA changed significantly over time irrespective of anticoagulation strategy (both P = .016), while the GSSG/GSH ratio approached a treatment-level difference (P = .067). Across the extracorporeal circuit, CRP increased significantly post-filter at both timepoints, MPO increased at 1h, and GSH showed an anticoagulation-dependent pre-to-post change at 1h. No significant differences were observed in secondary clinical outcomes.</p><p><strong>Conclusions: </strong>These pilot findings suggest that different anticoagulation strategies during CRRT may show domain-specific, rather than uniform, biological modulation, most evident within the neutrophil activation domain, with additional evidence of biomarker-specific kinetics across the extracorporeal circuit. These exploratory results are compatible with the concept that extracorporeal therapies may influence distinct domains differently, a hypothesis warranting confirmation in adequately powered, prospectively designed studies before implications for precision extracorporeal therapy can be drawn.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1932419"},"PeriodicalIF":2.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13643268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149139722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-17eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1825353
Max T Hukill, Andrea M Yeung, Talha H Imam
{"title":"Improvement in peritoneal dialysis exit-site infection rates in an integrated health care system in the United States.","authors":"Max T Hukill, Andrea M Yeung, Talha H Imam","doi":"10.3389/fneph.2026.1825353","DOIUrl":"https://doi.org/10.3389/fneph.2026.1825353","url":null,"abstract":"<p><strong>Introduction: </strong>Exit-site infections (ESIs) are a significant complication of peritoneal dialysis (PD) due to their potential to progress to peritonitis, leading to higher rates of morbidity, mortality, and PD dropout. ESI rates and trends have not been generally recorded or reported by established registries. To address this gap, we studied data from ten Kaiser Permanente Southern California (KPSC) hospitals over the last decade to report yearly PD ESI rates and examine trends over time.</p><p><strong>Methods: </strong>This is a historical cohort study using data provided by the Renal Registry of Southern California Permanente Medical Group (SCPMG) for ten KPSC hospitals. Each hospital provided quarterly data from 2014-2023 with number of patients and ESI rate, reported as episodes per 100 patient-months. We modeled quarterly ESI rates across all centers (2014-2023) using a Tweedie generalized linear mixed model with calendar year and program size as fixed effects, accounting for repeated measures within center.</p><p><strong>Results: </strong>The overall mean ESI rate across the study period was 0.86 episodes per 100 patient-months (95% CI: 0.68-1.05). The observed mean ESI rate was 1.26 (95% CI: 0.98-1.60) episodes per 100 patient-months in 2014, compared with 0.72 (95% CI: 0.42-1.07) in 2023. Each additional calendar year was associated with a 6.4% relative decrease in ESI rate (rate ratio [RR] 0.94, 95% CI 0.89-0.99, <i>p</i> = 0.011), corresponding to an estimated 45.1% decline in ESI rate over the study period (95% CI: 12.8-65.4%). Program size was not significantly associated with ESI rate after adjustment for calendar year (RR 0.76 per 100-patient increase, 95% CI 0.52-1.11, <i>p</i> = 0.15).</p><p><strong>Conclusion: </strong>We found a significant decline in ESI rates across ten KPSC hospitals from 2014 to 2023. This decline was not explained by growth in program size, suggesting that other factors-such as evolving infection prevention practices, staff training, or care coordination-may have contributed, though our data do not permit us to test these mechanisms directly. We encourage prospective or mechanism-specific studies to explore which factors are driving these improvements.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1825353"},"PeriodicalIF":2.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-16eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1985175
Peter Kotanko
{"title":"Editorial: Rising stars in nephrology 2024: illuminating the future of kidney health.","authors":"Peter Kotanko","doi":"10.3389/fneph.2026.1985175","DOIUrl":"https://doi.org/10.3389/fneph.2026.1985175","url":null,"abstract":"","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1985175"},"PeriodicalIF":2.9,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-14eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1917133
Dongmei Liu, Juan Mou, Hongmei Dai
{"title":"Case Report: A rare complication easily misdiagnosed as bacterial peritonitis: a case of sterile peritoneal dialysis-chemical peritonitis induced by amino-acid-based dialysate and literature review.","authors":"Dongmei Liu, Juan Mou, Hongmei Dai","doi":"10.3389/fneph.2026.1917133","DOIUrl":"10.3389/fneph.2026.1917133","url":null,"abstract":"<p><p>Peritoneal dialysis-chemical peritonitis induced by amino acid-based peritoneal dialysis solution is extremely rare. There are only a few reported case series of this condition. It can occur at any time during the use of amino acid dialysate, and most cases present with abdominal pain, cloudy effluent, and elevated peritoneal leukocyte counts, closely mimicking infectious peritonitis. This similarity poses a significant diagnostic challenge, as it is difficult to distinguish from bacterial peritonitis. Here, we report a case of peritoneal dialysis-chemical peritonitis associated with amino acid dialysate in a patient on peritoneal dialysis, aiming to raise awareness among clinicians of this rare entity that can be easily confused with infectious peritonitis. We also review its clinical characteristics, differential diagnosis, and management.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1917133"},"PeriodicalIF":2.9,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13616646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-08eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1932773
Lerui Wang, Minxia Li, Boyang Xu, Dan Shu
{"title":"Case Report: Advanced IgA nephropathy with psoriasis and a complex clinicopathologic course.","authors":"Lerui Wang, Minxia Li, Boyang Xu, Dan Shu","doi":"10.3389/fneph.2026.1932773","DOIUrl":"10.3389/fneph.2026.1932773","url":null,"abstract":"<p><p>Psoriasis and IgA nephropathy are immune-mediated disorders that may coexist, but the clinical meaning of this association remains uncertain. We report a 45-year-old man with psoriasis and progressive kidney dysfunction whose biopsy-proven IgA nephropathy presented with severe impairment of kidney function, heavy proteinuria, and mixed active and chronic histologic injury. At reassessment, serum creatinine was 463 μmol/L, estimated glomerular filtration rate was 12.1 mL/min/1.73 m², and pretreatment 24-hour urinary protein excretion ranged from 2.90 to 4.70 g. Kidney biopsy showed proliferative sclerosing IgA nephropathy, Oxford classification M1E1S1T2C0, with ischemic glomerular injury, microangiopathy, tubular atrophy, and interstitial fibrosis. Targeted-release budesonide and deucravacitinib were started together. Proteinuria fell to 0.62 g, serum creatinine decreased to 323 μmol/L, and a modest improvement in cutaneous disease activity was observed, with PASI decreasing from 2.4 to 1.6. After patient-initiated discontinuation of deucravacitinib, proteinuria increased and later declined after reintroduction. Following completion of the planned budesonide course, proteinuria continued to fall during deucravacitinib monotherapy, while kidney function deteriorated. This case is best interpreted as a clinicopathologic observation rather than proof of drug efficacy. Biopsy-defined activity and chronicity helped explain the discordant changes in proteinuria and kidney function, while the longitudinal course generated a testable but unproven hypothesis of a possible inflammatory connection between psoriasis and IgA nephropathy.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1932773"},"PeriodicalIF":2.9,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in nephrologyPub Date : 2026-09-08eCollection Date: 2026-01-01DOI: 10.3389/fneph.2026.1864394
Vijay Kher, Jatin Kothari, Jitendra Kumar, Sanjay Srinivasa, Prashant Kedlaya, Sivalingam M, Rammohan Bhat, Rajesh Nair, Mallikarjuna Hm, Reetesh Sharma, Vijay Kumar Sinha, Sreedhara C G, Jay Kumar Sharma, Iain C Macdougall
{"title":"Real-world use of pegylated erythropoietin in CKD-related anemia: an Indian modified Delphi consensus.","authors":"Vijay Kher, Jatin Kothari, Jitendra Kumar, Sanjay Srinivasa, Prashant Kedlaya, Sivalingam M, Rammohan Bhat, Rajesh Nair, Mallikarjuna Hm, Reetesh Sharma, Vijay Kumar Sinha, Sreedhara C G, Jay Kumar Sharma, Iain C Macdougall","doi":"10.3389/fneph.2026.1864394","DOIUrl":"10.3389/fneph.2026.1864394","url":null,"abstract":"<p><p>Anemia is a common and clinically significant complication of chronic kidney disease (CKD), contributing to impaired quality of life, increased cardiovascular risk, and higher mortality. Although erythropoiesis-stimulating agents (ESAs) remain the cornerstone of anemia management, conventional short- and intermediate-acting ESAs are associated with frequent dosing requirements, treatment burden, and variability in haemoglobin (Hb) control. Methoxy polyethylene glycol epoetin beta (MPG-EPO; PegEPO), a long-acting ESA with an extended half-life, enables less frequent administration and may offer advantages in Hb stabilization, treatment adherence, and patient convenience. Despite evidence supporting its efficacy and safety, the utilization of PegEPO in India remains limited. To provide practical guidance for the use of PegEPO in Indian clinical practice, a panel of 12 experienced Indian nephrologists participated in a three round modified Delphi consensus process. A comprehensive review of the available literature informed the development of consensus statements covering key domains, including patient selection, treatment initiation and dose adjustment, iron management, conversion from other ESAs, Hb targets and monitoring, safety considerations, and economic aspects of therapy. Consensus was achieved through iterative rounds of expert evaluation and discussion. The expert panel agreed that PegEPO offers efficacy and safety comparable to conventional ESAs in patients with CKD-associated anemia while providing additional advantages such as reduced dosing frequency, improved Hb stability, and the potential to enhance treatment adherence. The panel also identified practical considerations for optimizing PegEPO use in both dialysis-dependent and non-dialysis-dependent CKD populations within the Indian healthcare setting. This modified Delphi consensus provides evidence-informed, expert-driven recommendations to support individualized and pragmatic use of PegEPO in routine clinical practice. However, these statements represent expert consensus and are not intended as clinical guidelines; therefore, they should be adapted based on individual patient context and local clinical practice.</p>","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":"6 ","pages":"1864394"},"PeriodicalIF":2.9,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}